Is There any Concordance between of IHC with FISH in HER2-Positive Breast Cancer Patients?

Mehrdad Payandeh, Masoud Sadeghi, Edris Sadeghi, Alireza Janbakhsh

Open access · greenAbstract read

In one paragraph

Article in International journal of hematology-oncology and stem cell research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it

0cells of the map it votes in

5citing papers in PubMed

0.8field-weighted citation impact, top 26% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

Histology Agnostic Drug Development: An Updated Review.Cancers · 2024
Review
Age at Diagnosis of Breast Cancer in Iran: A Systematic Review and Meta-Analysis.Iranian journal of public health · 2021
Review
Relationship Study of The Verified H uman Epidermal Growth Factor Receptor 2 Amplification with Other Tumor Markers and Clinicohistopathological Characteristics in Patients with Invasive Breast Cancer, Using Chromogenic In Situ Hybridization.Cell journal · 2019
Article
The comparison of anthracycline-based and non-anthracycline-based regimens in adjuvant chemotherapy of HER2-positive non-metastatic breast cancers.Contemporary oncology (Poznan, Poland) · 2018
Article
Targeted therapeutic options and future perspectives for HER2-positive breast cancer.Signal transduction and targeted therapy
Review

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Mehrdad PayandehDepartment of Hematology and Medical Oncology, Kermanshah University of Medical Sciences, Kermanshah, Iran.

Masoud SadeghiStudents Research Committee, Kermanshah University of Medical Sciences, Kermanshah, Iran; Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran.

Edris SadeghiStudents Research Committee, Kermanshah University of Medical Sciences, Kermanshah, Iran; Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran.

Alireza JanbakhshDepartment of Infectious Diseases and Tropical Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran.

Kermanshah University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

DFSFISHHormone receptorsTrastuzumab

Identifiers

PMID28286614

PMCPMC5338281

OpenAlexW2266905063

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.